Compare Build A Bear Workshop Inc (BBW) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Build A Bear Workshop Inc vs Sanofi SA — how do they compare? Build A Bear Workshop Inc trades at $36.88 (market cap $467.15M), while Sanofi SA trades at $43.52 (market cap $104.57B). The key difference: Sanofi SA is far larger — about 223.8× Build A Bear Workshop Inc's market cap, and Sanofi SA pays the higher dividend (5.56%). Which is the better fit depends on your goals.
| BBW | SNY | |
|---|---|---|
Market Cap | $467.15M | $104.57B |
Sector | Consumer Cyclical | Health |
52-Week High | $75.85 | $52.34 |
52-Week Low | $29.84 | $41.33 |
Enterprise Value | $566.59M | $124.48B |
Dividend Yield | 2.47% | 5.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Build-A-Bear Workshop (BBW) trades at $36.86, up 6.19% today, with a bullish technical signal and strong analyst support. The stock exhibits attractive valuation metrics, including a P/E of 8.73 and P/S of 0.92, alongside robust profitability with a 10.48% net income margin and 35.87% ROE. Recent earnings have consistently beaten estimates, and the company maintains a debt-free balance sheet while executing a growth strategy focused on international expansion and brand partnerships.
The outlook for BBW is positive, driven by earnings momentum and a consensus price target of $62.50 implying significant upside. Key risks include near-term consumer spending volatility and execution of expansion plans, but strong fundamentals and shareholder returns via dividends support a favorable risk-reward profile for long-term investors.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Build A Bear Workshop Inc
Build-A-Bear is a global retailer specializing in customizable stuffed animals. It offers an interactive make-your-own experience where customers choose, stuff, and dress their furry friends in-store or online.
Read more on BBW →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
